Recently, antagonists of the kappa opioid receptor (KOR) have attracted significant attention due to their potential use in treating various central nervous system (CNS) disorders, especially mood disorders and substance abuse [1,2,3,4,5]. This evidence concerns the gene OPRK1 and mood disorder.